Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Endocyte Inc (ECYT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,167,600
  • Shares Outstanding, K 69,500
  • Annual Sales, $ 70 K
  • Annual Income, $ -55,060 K
  • 36-Month Beta 0.56
  • Price/Sales 16,809.55
  • Price/Cash Flow N/A
  • Price/Book 6.80

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.76 +31.66%
on 06/22/18
17.70 -5.08%
on 07/16/18
+2.28 (+15.70%)
since 06/18/18
3-Month
8.75 +92.00%
on 04/25/18
17.70 -5.08%
on 07/16/18
+7.07 (+72.66%)
since 04/18/18
52-Week
1.17 +1,335.90%
on 08/21/17
17.70 -5.08%
on 07/16/18
+15.39 (+1,091.49%)
since 07/18/17

Most Recent Stories

More News
The Market That Took BEAT Higher By 800% Could Do The Same For This Strong New Competitor

Cardiac monitoring is a $32 billion market, and the companies that are successfully navigating this space with new technology are seeing huge returns: IRTC is up 300% in 3 years, and BEAT up 800% in 5...

ECYT : 16.80 (-0.77%)
ZGNX : 59.20 (-3.11%)
Endocyte and ITM Announce Long-Term Supply Agreement for No-Carrier-Added Lutetium-177

Endocyte, Inc. (Nasdaq:ECYT), and ITM Isotopen Technologien Munchen AG (ITM), a group of specialized radiopharmaceutical companies, announced today that ITM's subsidiary, Isotope Technologies...

ECYT : 16.80 (-0.77%)
ITG : 22.61 (+1.34%)
Endocyte and ITM Announce Long-Term Supply Agreement for No-Carrier-Added Lutetium-177

Endocyte, Inc. (Nasdaq:ECYT), and ITM Isotopen Technologien Munchen AG (ITM), a specialized radiopharmaceutical group of companies, announced today that ITM´s subsidiary, Isotope Technologies Garching...

ECYT : 16.80 (-0.77%)
ITG : 22.61 (+1.34%)
Image Following Treatment with 177Lu-PSMA-617 Selected by Society of Nuclear Medicine and Molecular Imaging as Image of the Year

Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that an image from a Phase 2 study of Lu-PSMA-617, led by Dr....

ECYT : 16.80 (-0.77%)
Endocyte to Join the Russell 3000(R) Index

Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that its common stock has been selected for inclusion in the...

ECYT : 16.80 (-0.77%)
Endocyte Announces Presentations on PSMA-617 at the 2018 Society of Nuclear Medicine and Molecular Imaging Annual Meeting

Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced that multiple presentations related to Endocyte's PSMA-617...

ECYT : 16.80 (-0.77%)
Stock Performance Review on Exelixis and Three Other Biotech Stocks

Stock Research Monitor: ECYT, EPZM, and ESPR

ESPR : 43.76 (+2.63%)
ECYT : 16.80 (-0.77%)
EXEL : 21.33 (-0.05%)
EPZM : 13.55 (-0.37%)
Developing Cancer Treatment Trials Positive Indication for Biotech Market

PALM BEACH, Florida, June 12, 2018 /PRNewswire/ --

APTO : 3.29 (-2.08%)
ECYT : 16.80 (-0.77%)
PFE : 37.66 (+0.03%)
CORV : 3.94 (+2.60%)
MBRX : 1.73 (+1.76%)
Endocyte (ECYT) Up 5.1% Since Earnings Report: Can It Continue?

Endocyte (ECYT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

ECYT : 16.80 (-0.77%)
Endocyte Announces Enrollment of First Patient in Phase 3 VISION Trial of 177Lu-PSMA-617 in Prostate Cancer

Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted therapeutics for personalized cancer treatment, today announced the enrollment of the first patient in its global phase 3 VISION...

ECYT : 16.80 (-0.77%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More Share

Trade ECYT with:

Business Summary

Endocyte, Inc. is a biopharmaceutical company engaged in the development of therapies for the treatment of cancer and inflammatory diseases. The Company creates novel small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized targeted therapies. Endocyte, Inc. is based...

See More

Key Turning Points

2nd Resistance Point 17.40
1st Resistance Point 17.10
Last Price 16.80
1st Support Level 16.41
2nd Support Level 16.02

See More

52-Week High 17.70
Last Price 16.80
Fibonacci 61.8% 11.39
Fibonacci 50% 9.44
Fibonacci 38.2% 7.48
52-Week Low 1.17

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar